Kidney disease after hematopoietic stem cell transplant—treatment standard
Nephrology Dialysis Transplantation · 26.11.2025 · 40 (12) · 2268-2279
DOI: 10.1093/ndt/gfaf139 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 17.07.2025. Verfasst von Yu Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Kidney Diseases, Graft vs Host Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hematopoietic stem cell transplant (HSCT) is a well-established procedure for malignant and nonmalignant conditions. Despite its therapeutic benefits, kidney disease remains a common complication that significantly affects patient outcomes. Kidney injury post-HSCT manifests as acute kidney injury and chronic kidney disease, with multifactorial causes such as conditioning regimens, nephrotoxic drugs, graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (TA-TMA). Accurate diagnosis often requires a kidney biopsy due to overlapping risk factors and complex clinical presentations. This review summarizes current diagnostic and therapeutic standards, highlights advance in biomarkers and pathophysiology, and discusses targeted therapies such as rituximab for GVHD-related glomerulopathies and eculizumab for TA-TMA. Supportive care, immunomodulation, and early intervention remain critical. For patients progressing to end stage renal disease, renal replacement therapy and kidney transplantation post-HSCT offer viable long-term options. Despite these advances, challenges persist, including the need for noninvasive diagnostic tools and standardized management protocols. Future research into pathophysiology, biomarkers, and targeted therapies holds promise for improving outcomes in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China.
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affliated Hospital of Medical School, Nanjing University, Nanjing, China.
ORCID-Profile: Xianghua Huang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Fu, W., & Huang, X. (2025). Kidney disease after hematopoietic stem cell transplant—treatment standard. Nephrology Dialysis Transplantation, 40(12), 2268-2279. https://doi.org/10.1093/ndt/gfaf139
Vancouver
Zhang Y, Fu W, Huang X. Kidney disease after hematopoietic stem cell transplant—treatment standard. Nephrology Dialysis Transplantation. 2025;40(12):2268-2279. doi:10.1093/ndt/gfaf139
BibTeX
@article{Zhang2025,
author = {Zhang, Yu and Fu, Weiwei and Huang, Xianghua},
title = {Kidney disease after hematopoietic stem cell transplant—treatment standard},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {12},
pages = {2268--2279},
doi = {10.1093/ndt/gfaf139}
}
EUVIMED